Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps

Nature Reviews Cancer

Volumn 11, Issue 11, 2011, Pages 805-812

  Sharma, Padmanee ^a,b   Wagner, Klaus ^a   Wolchok, Jedd D ^b   Allison, James P ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DACARBAZINE; GP100 VACCINE; INTERLEUKIN 2; IPILIMUMAB; PEPTIDE VACCINE; PROSTVAC; PROVENGE; SORAFENIB; TEMOZOLOMIDE; TICILIMUMAB; UNCLASSIFIED DRUG; VIRUS VACCINE;

CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; IMMUNOSURVEILLANCE; MAINTENANCE DRUG DOSE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MONITORING, IMMUNOLOGIC; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; TISSUE EXTRACTS;

EID: 80054875641     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3153     Document Type: Review

References (46)

1. Burnet, F. M. Immunological aspects of malignant disease. Lancet 1, 1171-1174 (1967).
2. Burnet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1-27 (1970).
3. Thomas, L. On immunosurveillance in human cancer. Yale J. Biol. Med. 55, 329-333 (1982).
4. Kaplan, D. H. et al. Demonstration of an interferon-γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556-7561 (1998).
5. Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001).
6. Lasaro, M. O. & Ertl, H. C. Targeting inhibitory pathways in cancer immunotherapy. Curr. Opin. Immunol. 22, 385-390 (2010).
7. Schreibelt, G. et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. 59, 1573-1582 (2010).
8. Speiser, D. E. & Romero, P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin. Immunol. 22, 144-154 (2010).
9. Rosenberg, S. A. & Dudley, M. E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21, 233-240 (2009).
10. Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002).
11. Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
12. Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924 (2011).
13. Kershaw, M. H. et al. A phase I study of adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115 (2006).
14. Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
15. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733 (2011).
16. Schwartzentruber, D. et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119-2127 (2011).
17. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
18. Kantoff, P. W. et al. Overall survival analysis of a phase II randomized controlled trial of a proxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099-1105 (2010).
19. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
20. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA4 blockade. Science 271, 1734-1736 (1996).
21. Van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic lymphocyte-associated antigen 4 (CTLA4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
22. Quezada, S. A. et al. CTLA4-blockade and GMCSF combination immunotherapy alters the intra-tumor balance of effector and regulatory T cells. J. Clin. Invest. 116, 1935-1945 (2006).
23. Kirkwood, J. M. et al. Phase II trial of tremelimumab (CP675206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 16, 1042-1048 (2010).
24. Camacho, L. H. et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27, 1075-1081 (2009).
25. Ribas, A. Clinical development of the anti-CTLA4 antibody tremelimumab. Semin. Oncol. 37, 450-454 (2010).
26. Marshall, M. A., Ribas, A. & Huang, B. Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. J. Clin. Oncol. 28 (Suppl.), Abstract 2609 (2010).
27. hi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105, 14987-14992 (2008).
28. hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues. Proc. Natl Acad. Sci. USA 106, 2729-2734 (2009).
29. Carthon, B. C. et al. Preoperative CTLA4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16, 2861-2871 (2010).
30. Vonderheide, R. H. et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16, 3485-3494 (2010).
31. Yuan, J. et al. CTLA4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105, 20410-20415 (2008).
32. Peggs, K. S., Quezada, S. A., Sharma, P. & Allison, J. P. Cancer immunotherapy. In Cancer Medicine 8th edn 175-189 (People's Medical Publishing House, Shelton, Connecticut, 2010).
33. Wolchok, J. D. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11, 155-164 (2010).
34. Salgaller, M., Marincola, F., Cormier, J. & Rosenberg, S. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56, 4749-4757 (1996).
35. Korn, E. L. et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26, 527-534 (2008).
36. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
37. Sznol, M. et al. Safety and antitumor activity of biweekly MDX1106 (Anti-PD1, BMS936558/ONO4538) in patients with advanced refractory malignancies. J. Clin. Oncol. 28 (Suppl.), Abstract 2506 (2010).
38. Saenger, Y. M. & Wolchok, J. D. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 8, 1 (2008).
39. O'Day, S. et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21, 1712-1717 (2010).
40. Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
41. Kane, R. C. et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 12, 7271-7278 (2006).
42. Spira, D. et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad. Radiol. 18, 89-96 (2010).
43. Suzuki, C. et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28, 329-344 (2008).
44. Gajewski, T. F., Louahed, J. & Brichard, V. G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 16, 399-403 (2010).
45. Haining, W. N. & Wherry, E. J. Integrating genomic signatures for immunologic discovery. Immunity 32, 152-161 (2010).
46. Kirkwood, J. M. et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine +/- granulocyte-monocyte colony-stimulating factor and/or IFNα2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin. Cancer Res. 15, 1443-1451 (2009).